Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease

Verve的领先项目旨在通过针对与心血管疾病密切相关的基因，以单次剂量实现终生的心血管风险降低。

Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise

礼来在心脑代谢疾病和基因药物方面的能力与Verve的愿景和专业知识高度互补。

INDIANAPOLIS

印第安纳波利斯

,

，

June 17, 2025

2025年6月17日

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and

/PRNewswire/ -- 礼来公司（纽约证券交易所代码：LLY）和

Verve Therapeutics, Inc.

Verve Therapeutics, Inc.

(Nasdaq: VERV), a

(Nasdaq: VERV)，一家

Boston

波士顿

-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve.

基于临床阶段的公司，开发心血管疾病基因药物，今天宣布了礼来收购Verve的最终协议。

Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Verve's lead program (VERVE-102) is a potential first-in-class

Verve正在开发一条基因编辑药物的管线，旨在通过可能终身只需一次的治疗来解决动脉粥样硬化性心血管疾病（ASCVD）的致病因素。Verve的主导项目（VERVE-102）是一种潜在的首创药物。

in vivo

体内

gene editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health. The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD).

针对PCSK9的基因编辑药物，PCSK9是一种与胆固醇水平和心血管健康相关的基因。该疗法可能适用于患有杂合子家族性高胆固醇血症（HeFH）的人群，HeFH是动脉粥样硬化性心血管疾病（ASCVD）的一个亚型，在普通人群中的发病率为1/250，同时也适用于某些早发冠状动脉疾病（CAD）患者。

VERVE-102 is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the .

VERVE-102正在一项Ib期临床试验中进行评估，并已被授予快速通道资格。

U.S. Food and Drug Administration

美国食品药品监督管理局

.

。

'VERVE-102 has the potential to be the first

‘VERVE-102有潜力成为第一个

in vivo

体内

gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' said Ruth Gimeno, Lilly group vice president,

基因编辑疗法适用于广泛的患者群体，并且可以将心血管疾病的治疗模式从慢性护理转变为一次性治疗，礼来集团副总裁 Ruth Gimeno 表示。

Diabetes and Metabolic Research

糖尿病与代谢研究

and Development. 'Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space.'

和开发。 “礼来很高兴欢迎我们的Verve同事加入礼来，并继续开发这些有前景的潜在新药，旨在改善心血管疾病患者的治疗效果，并满足这一领域显著未被满足的医疗需求。”

'Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future,' said

“Verve的创立只有一个使命：将心血管疾病的治疗从慢性护理转变为单剂量的未来，”

Sekar Kathiresan

艾瑞卡坦·卡瑟里山

, M.D., co-founder and chief executive officer of

，医学博士，联合创始人兼首席执行官

Verve Therapeutics

维erve治疗学

. 'In just seven years, our team has progressed three

‘仅仅七年时间，我们的团队就进步了三

in vivo

体内

gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly. Lilly shares our vision, and we believe their global research, clinical, regulatory and commercial capabilities will help to accelerate the development of our medicines.

基因编辑产品，目前已有两款进入临床阶段。现在，我们将与理想的合作伙伴礼来共同迈出药物开发旅程的下一步。礼来与我们有着相同的愿景，我们相信礼来全球的研发、临床、法规和商业能力将有助于加速我们药物的开发进程。

My deepest thanks to the entire Verve team for their expertise, creativity, and grit. We are grateful to the investigators and patients who have contributed to the success of our clinical trials so far. Under Lilly's stewardship, we are excited to realize the next chapter in cardiovascular care where a single treatment can lead to lifelong reduction of cardiovascular risk factors and make life better for millions of patients living with cardiovascular disease.'.

我谨向整个Verve团队表达最深切的感谢，他们的专业精神、创造力和坚韧不拔是我们成功的关键。我们衷心感谢那些为我们的临床试验做出贡献的研究人员和患者。在礼来公司的引领下，我们激动地迈向心血管护理的新篇章，在这里，单次治疗便可实现终生降低心血管风险因素的目标，并改善数百万心血管疾病患者的生活质量。

Under the terms of the agreement, Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of

根据协议条款，礼来公司将开始要约收购维夫所有已发行股份，收购价格为

$10.50

10.50美元

per share in cash (an aggregate of approximately

每股现金（总计约

$1.0 billion

10亿美元

) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional

) 在收盘时支付，加上每股一个不可交易的或有价值权（CVR），使持有人有权额外获得最多

$3.00

3.00美元

per share, for a total potential consideration of up to

每股，总潜在对价高达

$13.50

13.50美元

per share in cash without interest (an aggregate of up to approximately

每股现金，不计利息（总计高达约

$1.3 billion

13亿美元

). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a

). CVR持有者将在首位患者接受VERVE-102治疗ASCVD时有权获得或有支付，

U.S.

美国

Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. There can be no assurance that any payments will be made with respect to the CVR. The transaction is not subject to any financing condition and is expected to close in the third quarter of 2025, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Verve's common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of Verve that are not tendered in the tender offer through a second step merger at the same consideration as paid in the tender offer..

在CVR结束或终止的十周年当天或之前进行第三阶段临床试验。无法保证会就CVR支付任何款项。本次交易不受任何融资条件的限制，预计将在2025年第三季度完成，但需满足惯常的交割条件，包括Verve多数流通股的要约收购。在成功完成要约收购后，Lilly将通过第二步合并以与要约收购相同的对价收购未在要约收购中出售的Verve股份。

The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve's common stock ended on

在收盘时支付的购买价格较Verve普通股截至当日的30天成交量加权平均交易价格溢价约113%。

June 16, 2025

2025年6月16日

, the last trading day before the announcement of the transaction. Verve's board of directors unanimously recommends that Verve's stockholders tender their shares in the tender offer.

，本次交易宣布前的最后一个交易日。Verve董事会一致建议Verve的股东在要约收购中出售他们的股份。

To demonstrate their commitment to the transaction,

为了证明他们对这笔交易的承诺，

Sekar Kathiresan

斯卡·卡瑟里森

,

，

Andrew Ashe

安德鲁·阿什

and entities affiliated with GV have signed tender and support agreements whereby they agreed, subject to certain terms and conditions, to tender their shares in the tender offer. The shares subject to the agreements that are beneficially owned by such stockholders represent a total of approximately 17.8% of Verve's outstanding common stock..

和与GV有关的实体签署了投标和支持协议，根据这些协议，他们同意在某些条款和条件的约束下，将他们在要约收购中所持的股份进行投标。这些股东通过协议所涉及的股份占Verve已发行普通股总数的约17.8%。

Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

礼来公司将按照公认会计原则 (GAAP) 在交易结束时确定该交易的会计处理方法。此后，该交易将反映在礼来的财务结果和财务指导中。

For

为了

Lilly, Kirkland & Ellis LLP

莉莉，柯克兰和埃利斯律师事务所

is acting as legal counsel. For Verve,

正在担任法律顾问。对于Verve，

Centerview Partners LLC

森特尔维尤合伙人有限责任公司

and

和

Guggenheim Securities, LLC

古根海姆证券有限责任公司

are acting as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP, is acting as legal counsel.

担任财务顾问，而保罗·韦斯、里夫金德、沃顿和加里森律师事务所则担任法律顾问。

About

关于

Verve Therapeutics

维erve治疗学公司

Verve Therapeutics, Inc.

Verve治疗公司

(Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a).

（纳斯达克：VERV）是一家临床阶段的公司，正在开发一类新的基因药物用于治疗心血管疾病，这些药物有潜力将治疗方式从慢性疗法转变为单疗程基因编辑药物。该公司的主要项目——VERVE-102、VERVE-201 和 VERVE-301——针对动脉粥样硬化的三个脂蛋白驱动因素：低密度脂蛋白、富含甘油三酯的脂蛋白和脂蛋白(a)。

VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels.

VERVE-102旨在永久关闭肝脏中的PCSK9基因，最初正在开发用于治疗杂合子家族性高胆固醇血症，最终用于治疗已确诊动脉粥样硬化性心血管疾病（ASCVD）且持续受高密度脂蛋白胆固醇水平影响的患者。

VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia.

VERVE-201旨在永久关闭肝脏中的ANGPTL3基因，最初正被开发用于难治性高胆固醇血症，即尽管接受了最大耐受标准治疗，患者仍具有高水平的低密度脂蛋白胆固醇，以及纯合子家族性高胆固醇血症。

VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit .

VERVE-301旨在永久关闭LPA基因以降低脂蛋白(a)水平。脂蛋白(a)是经过基因验证的、独立的心血管疾病、缺血性中风、血栓形成和主动脉瓣狭窄的风险因素。欲了解更多信息，请访问。

www.VerveTx.com

www.VerveTx.com

.

。

About Lilly

关于礼来公司

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治疗手段，以改善世界各地人们的生活。近150年来，我们一直在开创改变生命的发现，如今我们的药物帮助了全球数千万人。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转变为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

每迈向更健康的世界一步，我们都被一个目标所激励：让数百万人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药品可及且价格合理。欲了解更多信息，请访问。

Lilly.com

礼来公司官网

and

和

Lilly.com/news

Lilly.com/新闻

, or follow us on

，或者关注我们

Facebook

Facebook

,

，

Instagram

Instagram

, and

，以及

LinkedIn

领英

. F-LLY

. F-LLY

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements regarding Lilly's proposed acquisition of Verve, regarding prospective benefits of the proposed acquisition and Verve's gene editing programs for cardiovascular disease, regarding potential contingent consideration amounts and terms, regarding the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition, regarding Verve's product candidates and ongoing clinical and preclinical development, regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines, and regarding the accounting treatment of the potential acquisition under GAAP and its potential impact on Lilly's financial results and financial guidance.

本新闻稿包含关于礼来公司拟收购Verve的前瞻性声明，涉及拟议收购的预期收益及Verve在心血管疾病领域的基因编辑项目，涉及潜在的或有对价金额与条款，涉及拟议要约收购的发生、方式和时间安排以及拟议收购的完成，涉及Verve的产品候选药物及其正在进行的临床和临床前开发，涉及礼来公司在心血管疾病领域项目的开发及推动心脏代谢健康药物的进展，以及涉及根据GAAP对该潜在收购的会计处理及其可能对礼来财务业绩和财务指引的影响。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to consummating the proposed acquisition and any competing offers or acquisition proposals for Verve, drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the potential acquisition and its potential impact on its financial results and financial guidance, uncertainties as to how many of Verve's stockholders will tender their stock in the tender offer, the effects of the proposed acquisition (or the announcement thereof) on Verve's stock price, relationships with key third parties or governmental entities, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, tra.

所有非历史事实的陈述均为可能被视为前瞻性陈述的陈述。前瞻性陈述反映了当前的信念和期望；然而，这些陈述涉及固有的风险和不确定性，包括关于完成拟议收购以及任何对Verve的竞争性报价或收购提议、药物研究、开发和商业化、礼来公司对潜在收购会计处理的评估及其对其财务结果和财务指导的潜在影响、不确定Verve的多少股东将接受要约收购、拟议收购（或其公告）对Verve股价的影响、与关键第三方或政府实体的关系、监管变化和发展、全球经济状况的宏观影响，包括贸易及其他全球争端和中断，包括与关税相关的争端和中断等。

U.S. Securities and Exchange Commission

美国证券交易委员会

. Except as required by law, neither Lilly nor Verve undertakes any duty to update forward-looking statements to reflect events after the date of this filing.

除非法律要求，礼来公司和Verve均不承担更新前瞻性声明以反映本文件日期之后事件的任何责任。

Additional Information about the Acquisition and Where to Find It

关于收购的更多信息及其获取途径

The tender offer for all of the outstanding shares of Verve described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer.

本通讯中描述的对Verve所有已发行股份的要约收购尚未开始。本通讯仅供参考，既不是购买证券的要约，也不是出售证券的要约邀请，且不能替代礼来公司及其收购子公司在要约收购开始时将向美国证券交易委员会提交的要约收购材料。

A solicitation and offer to buy outstanding shares of Verve will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary intend to file with the .

收购要约和购买Verve已发行股份的提议，将仅根据礼来公司及其收购子公司打算提交的要约材料进行。

SEC

证券交易委员会

. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and Verve will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO.

在要约收购开始时，礼来公司及其收购子公司将根据附表TO提交要约收购材料，而Verve公司将就该要约收购向美国证券交易委员会（SEC）提交附表14D-9上的征求/建议声明。要约收购材料（包括购买要约、相关转交函及某些其他要约收购文件）和征求/建议声明将包含有关拟议收购及交易各方的重要信息。

INVESTORS AND STOCKHOLDERS OF VERVE ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF VERVE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER.

VERVE的投资者和股东被敦促在这些文件可用时仔细阅读（以及每份文件可能不时的修订或补充），因为它们将包含VERVE的投资者和股东在做出任何关于在要约收购中出售其普通股的决定之前应考虑的重要信息。

The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Verve at no expense to them at Lilly's website at investor.lilly.com and (once they become available) will be mailed to the stockholders of Verve free of charge.

要约收购材料（包括购买要约和相关的转送函），以及征集/建议声明，将免费提供给Verve的所有股东，可通过礼来公司网站 investor.lilly.com 查阅，并且（一旦可用）将免费邮寄给Verve的股东。

The information contained in, or that can be accessed through, Lilly's website is not a part of, or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC's website at .

礼来公司网站中包含或可通过其访问的信息，不构成本文的一部分，也不通过引用并入本文。要约收购材料（包括购买要约和相关的转送函），以及征集/建议声明，也将免费在 SEC 的网站上提供。

www.sec.gov

www.sec.gov

. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Verve file annual, quarterly, and current reports, proxy statements and other information with the

除购买要约、相关的转递函和某些其他要约文件以及征集/建议声明外，礼来公司和Verve还向证券交易委员会提交年度、季度和当前报告、代理声明及其他信息。

SEC

证券交易委员会

. You may read any reports, statements or other information filed by Lilly and Verve with the SEC for free on the

您可以在以下位置免费阅读礼来和Verve向美国证券交易委员会提交的任何报告、声明或其他信息：

SEC's

证券交易委员会的

website at

网站位于

www.sec.gov

www.sec.gov

.

。

Refer to:

参考：

Ashley Hennessey

艾希礼·亨尼西

;

；

gentry_ashley_jo@lilly.com

gentry_ashley_jo@lilly.com

; 317-416-4363 (Media)

；317-416-4363（媒体）

Michael Czapar

迈克尔·查帕尔

;

；

czapar_michael_c@lilly.com

czapar_michael_c@lilly.com

; 317-617-0983 (Investors)

；317-617-0983（投资者）

Ashlea Kosikowski

阿什莉娅·科西科夫斯基

;

；

ashlea@1abmedia.com

ashlea@1abmedia.com

(Verve)

（Verve）

View original content to download multimedia:

查看原始内容以下载多媒体：

https://www.prnewswire.com/news-releases/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302483684.html

https://www.prnewswire.com/news-releases/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302483684.html

SOURCE

源代码

Eli Lilly and Company

礼来公司